Be part of the knowledge.™

Gastroenterology and Hepatology

182

LikeLikedUnlike

31-45 of 71

Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
MinuteCE®
Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
- Børge G. Nordestgaard, MD, DMSc
  Peer
- Kausik Ray, MBChB, MD, MPhil
  Peer
1.00 program credits
APOC3 Inhibition: A Novel Approach to Lowering TGs
MinuteCE®
APOC3 Inhibition: A Novel Approach to Lowering TGs
- Børge G. Nordestgaard, MD, DMSc
  Peer
- Kausik Ray, MBChB, MD, MPhil
  Peer
1.00 program credits
Latest Clinical Trial Outcomes and Breakthroughs for FCS
MinuteCE®
Latest Clinical Trial Outcomes and Breakthroughs for FCS
- Daniel Gaudet, MD, PhD
  Peer
- Pam R. Taub, MD, FACC, FASPC
  Peer
1.00 program credits
SHTG: Defining the Unmet Clinical Need
MinuteCE®
SHTG: Defining the Unmet Clinical Need
- Pam R. Taub, MD, FACC, FASPC
  Peer
- Kausik Ray, MBChB, MD, MPhil
  Peer
1.00 program credits
SHTG: Decoding the Latest Clinical Trial Outcomes
MinuteCE®
SHTG: Decoding the Latest Clinical Trial Outcomes
- Pam R. Taub, MD, FACC, FASPC
  Peer
- Kausik Ray, MBChB, MD, MPhil
  Peer
1.00 program credits
Remnant Cholesterol: The Missing Link in ASCVD risk
MinuteCE®
Remnant Cholesterol: The Missing Link in ASCVD risk
- Børge G. Nordestgaard, MD, DMSc
  Peer
- Kausik Ray, MBChB, MD, MPhil
  Peer
1.00 program credits
advertisement
Targeting Mixed Hyperlipidemia with APOC3 Inhibition
MinuteCE®
Targeting Mixed Hyperlipidemia with APOC3 Inhibition
- Pam R. Taub, MD, FACC, FASPC
  Peer
- Kausik Ray, MBChB, MD, MPhil
  Peer
1.00 program credits
The Road Ahead: What's on the Horizon for FCS and SHTG Management
MinuteCE®
The Road Ahead: What's on the Horizon for FCS and SHTG Management
- Pam R. Taub, MD, FACC, FASPC
  Peer
- Prof. Kausik Ray
  Peer
1.00 program credits
MinuteCE®
Chemotherapy Strategies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- Eileen O’Reilly, MD
  Peer
- Efrat Dotan, MD
  Peer
0.25 credits 2 episodes
MinuteCE®
Differentiating First-Line Treatment Selection: Combination Immunotherapy and Chemotherapy Regimens for Metastatic ESCC
- Harry Yoon, MD
  Peer
- Jaffer Ajani, MD
  Peer
0.75 credits 7 episodes
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
MinuteCE®
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
- Jaffer Ajani, MD
  Peer
0.75 program credits
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
MinuteCE®
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
- Harry Yoon, MD
  Peer
0.75 program credits
advertisement
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
MinuteCE®
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
- Harry Yoon, MD
  Peer
- Jaffer Ajani, MD
  Peer
0.75 program credits
ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
MinuteCE®
ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
- Harry Yoon, MD
  Peer
- Jaffer Ajani, MD
  Peer
0.75 program credits
Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
MinuteCE®
Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
- Harry Yoon, MD
  Peer
- Jaffer Ajani, MD
  Peer
0.75 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended